Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13-week double-blind study of modified-release AFQ056 for L-dopa induced dyskinesias in Parkinson's disease
2011-002074-23Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AFQ056 arm with Placebo arm (2 arms). Primary endpoint: Change in modified AIMS total score from baseline to Week 12. Started Feb 2012; status: completed.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2011-002074-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002074-23.